![](https://www.elaia.com/wp-content/uploads/2024/06/Logo-Biophta-rgb.png)
BIOPHTA aims to radically improve the efficacy of eye treatments by leveraging the first 7-day continuous microdosing pharmaceutical form.
Entrepreneurs
Jean Garrec
Jean Cuiné
Elaia Team
Florian Denis
Related articles
![](https://www.elaia.com/wp-content/uploads/2024/06/medium_2024-06-03-6331963f7e.jpg)
BIOPHTA, a preclinical biotech company developing a game-changing technology for the treatment of eye diseases, has just closed a € 6.5 million Seed round to bring its patented technology to clinical development. This funding round was led by leading European VCs – UI Investissement (via the Pertinence Invest 2 Fund, advised by Mérieux Equity Partners), Elaia and GO Capital – as well as one major ophthalmology player, Unither Pharmaceuticals and HTL Biotechnology, the global leader in production and development of pharma grade biopolymers.
2024.06.03 / 3min read.